Trial Profile
A Study Assessing The Real-World Efficacy And Safety Of Paritaprevir/Ritonavir, Ombitasvir And Dasabuvir (PrOD) ± Ribavirin In Elderly Patients With Hepatitis-C Virus Infection (HCV) Genotype 1b Compensated Cirrhosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2019
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 26 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017.